SRX Global Inc. (SRXH) - Form 8-K Summary
Business Context and Reporting Period
Company: SRX Global Inc.
Filing Date: August 27, 2026 (Report Date: September 2, 2026)
Event: Entry into a Material Definitive Agreement (Item 1.01).
Counterparty: CERo Therapeutics Holdings, Inc. ("CERO").
SRX Global Inc. completed a secured financing transaction with CERO, consolidating previous convertible grid promissory notes into a new Consolidated Senior Secured Promissory Note.
Key Financial Metrics and Transaction Terms
| Metric | Value |
|---|---|
| Consolidated Previous Notes | $5,666,108.77 |
| Initial Advance (Aug 27, 2026) | $775,665.00 |
| Additional Advance Capacity | Up to $6,000,000 |
| Maximum Aggregate Loan Amount | $11,666,108.77 |
| Interest Rate (Standard) | 10% per annum |
| Interest Rate (Event of Default) | Lesser of 24.99% or maximum legal rate |
| Maturity Date | October 15, 2026 |
Use of Proceeds: CERO intends to use funds for outstanding trade payables and working capital.
Collateral: First-priority security interest in CERO's subsidiary stock and substantially all subsidiary assets, including intellectual property and clinical trial data for CER-1236.
Material Changes and Structure
- Debt Consolidation: The transaction consolidates outstanding notes totaling approximately $5.67 million into a single secured instrument.
- Liquidity Extension: Provides CERO with access to up to $6 million in additional funding, subject to budget adherence and no Event of Default.
- Security Package: Includes a Pledge Agreement, Asset Security Agreement, and an unconditional Guaranty of Payment by CERO's wholly-owned subsidiary.
- Prepayment Restrictions: CERO cannot prepay without SRX's written consent, except in connection with a change of control.
Outlook, Risks, and Contingencies
Extension Option: SRX may extend the maturity date for up to four consecutive 30-day periods if no Event of Default exists.
Events of Default: Include payment defaults, covenant breaches, bankruptcy, failure to use proceeds per budget, Material Adverse Effect, or invalidity of transaction documents. Upon default, SRX may accelerate the debt and exercise remedies against collateral.
Regulatory Status: The Note was issued in a private transaction under Section 4(a)(2) and Rule 506(b) exemptions; it is not registered under the Securities Act.
Investor Verification Checklist
- Verify the status of CERO's budget and ability to service the $11.67 million maximum debt load by the October 15, 2026 maturity.
- Review the specific terms of the "Material Adverse Effect" clause and cross-default provisions in the full Note text (Exhibit 10.1).
- Assess the valuation and enforceability of the pledged collateral, specifically the CER-1236 cell therapy assets and subsidiary equity.
- Monitor CERO's trade payable obligations and working capital needs to determine the likelihood of utilizing the full $6 million additional advance capacity.
- Confirm whether any prior "Previous Notes" had different terms that were superseded by this consolidation.